Herbal supplement with TACE to prevent liver cancer recurrence
Part of Cancer, Digestive system clinical trials.
This trial tests whether taking a herbal supplement (icariin soft capsules) along with a standard liver cancer treatment called TACE (chemoembolization) can help prevent cancer from returning after you've had it removed. It's for people with high-risk features that make recurrence more likely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with hepatocellular carcinoma (HCC), a type of liver cancer.
- You have already had surgery or an ablation procedure to remove the cancer, and you have recovered from it.
- Your cancer has certain features that make it more likely to come back, such as being large, having multiple tumors, or showing signs of blood vessel invasion.
- Your liver function is relatively good (Child-Pugh class A or early B).
- You do not have major blood vessel invasion or other serious health conditions that would prevent treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
Hear when a new Hepatocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.